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Abstract: Neuroserpin (NS) is a member of the serine protease inhibitors superfamily. Specific point 
mutations are responsible for its accumulation in the endoplasmic reticulum of neurons that leads 
to a pathological condition named familial encephalopathy with neuroserpin inclusion bodies 
(FENIB). Wild-type NS presents two N-glycosylation chains and does not form polymers in vivo, 
while non-glycosylated NS causes aberrant polymer accumulation in cell models. To date, all in 
vitro studies have been conducted on bacterially expressed NS, de facto neglecting the role of 
glycosylation in the biochemical properties of NS. Here, we report the expression and purification 
of human glycosylated NS (gNS) using a novel eukaryotic expression system, LEXSY. Our results 
confirm the correct N-glycosylation of wild-type gNS. The fold and stability of gNS are not altered 
compared to bacterially expressed NS, as demonstrated by the circular dichroism and intrinsic 
tryptophan fluorescence assays. Intriguingly, gNS displays a remarkably reduced polymerisation 
propensity compared to non-glycosylated NS, in keeping with what was previously observed for 
wild-type NS in vivo and in cell models. Thus, our results support the relevance of gNS as a new in 
vitro tool to study the molecular bases of FENIB. 
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1. Introduction 
Neuroserpin (NS) is a human protein mainly expressed in the nervous system [1]. This protein 
is ascribed to the serine protease inhibitor (serpin) superfamily with which it shares the conserved 
serpin fold and mechanism of action [1,2]. Even though its physiological roles are not completely 
elucidated, NS activity is involved in memory, learning, and both synaptic and neurovascular 
compartment plasticity [3–5]. NS, as any member of the serpin superfamily, is characterised by the 
presence of a long and flexible loop, named the reactive centre loop (RCL), essential for its 
physiological function [6,7]. The RCL is recognized by the tissue plasminogen activator (tPA), the 
target protease [8]. Upon binding to NS, tPA hydrolyses the RCL loop at position Arg362 with the 
concomitant formation of acyl complex NS-tPA. The RCL cleavage triggers a major structural 
rearrangement in which the N-terminal portion of the cleaved RCL is inserted into the central ß-sheet 
A between strands 3A and 5A [9]. Typically, in serpins, such conformational change causes the 
disruption of the protease active site and prevents the hydrolysis of the acyl-complex, rendering this 
covalent complex extremely stable over time [10]. During the conformational change from the native 
to the RCL-cleaved form, a consistent stabilization of the serpin molecule takes place, yielding a 
cleaved form that is hyper-stable [11]. However, opposite to other serpin-protease pairs, the NS-tPA 
complex is short-living and rapidly dissociates at physiological pH, releasing free cleaved NS and 
active tPA [6,12,13]. Another serpin inhibitor of tPA, plasminogen activator inhibitor-1 (PAI1), is 
instead forming a long-living acyl-complex whose dissociation has never been observed [12]. 
Compared to PAI1, NS discriminates between tPA and uPA (urokinase-type plasminogen activator), 
and between the single- or double-chain tPA [12]. The pH also plays an important role in the stability 
of the NS-tPA complex [13]. Lee et al. demonstrated that strands sC1 and sC2 and helices hCD and 
hE contribute to the recruitment of tPA and to the stabilization of the NS-tPA complex [14]. 
Monomeric NS can access a third conformation, the latent fold, where the uncleaved RCL is inserted 
in the β-sheet A, similar to the cleaved conformation [2,11]. Both these NS conformations are 
extremely stable and unable to load, and consequently to inhibit, tPA.  
NS mutations are responsible for the onset of familial encephalopathy with neuroserpin 
inclusion bodies (FENIB), a severe and fatal serpinopathy characterized by progressive 
neurodegeneration. Epilepsy, cognitive impairment and dementia are the main clinical symptoms 
reported for the patients. FENIB is a rare and autosomally dominant genetic disorder for which the 
age of onset and the severity of clinical manifestations are strictly correlated to the specific mutation 
carried by the patient [15]. There are six known point mutations related to FENIB: S49P, S52R, H338R, 
G392E, G392R, and L47P [16–19]. Mutated NS undergoes polymerization and deposits within the 
endoplasmic reticulum of neurons, where it accumulates as inclusion bodies [17,20] causing a poorly 
characterized neuronal toxicity that involves oxidative stress and apoptosis [21]. The structural 
features of polymeric NS are not completely understood yet. In all the polymerisation models 
reported for the prototypical serpin alpha-1 antitrypsin, the RCL loop exerts a crucial role and is 
thought to be inserted in β-sheet A of the neighbouring monomers as part of the intermolecular link 
[22,23], or intramolecularly to provide flexibility for the domain swap that links monomers into 
polymeric chains [23].  
The monomeric and polymeric NS conformers can be discriminated using specific structural 
signatures in different spectroscopic techniques: the circular dichroism (CD) spectra of latent and 
polymeric NS show a more intense signal compared to native NS [24,25], and Noto et al. reported the 
possibility to profile each conformer using protein intrinsic fluorescence, i.e., the emission spectra of 
tryptophan or tyrosine residues within NS [25]. 
As many other secreted proteins, human NS is glycosylated in vivo and presents two N-linked 
glycosylation chains on asparagine residues N157 and N321. A third aberrant glycosylation chain 
added in N401 has been observed for the G392E pathological NS mutant and causes abundant 
polymer accumulation within the endoplasmic reticulum in cell models of FENIB [15,26–30]. The 
presence of the post-translational modifications is known to play an important role in the NS protein 
quality control [29] and stability [29,30]. In particular, Schipanski et al. [29] and Moriconi et al. [30] 
reported that the glycosylation plays a pivotal role in keeping NS in its physiological monomeric 
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state in HEK and COS-7 cells. When the physiologic glycosylation pattern is artificially impaired by 
the specific mutation of N157 and N321 residues, the behaviour of wild-type NS is reminiscent of the 
pathological FENIB mutants, and the accumulation of NS polymers was observed in the endoplasmic 
reticulum [30]. The effect was additive and the abrogation of both glycosylation sites caused an even 
more pronounced accumulation of NS polymers [30].  
To date, only rat NS has been expressed glycosylated [31]; indeed, all the in vitro biochemical 
and biophysical studies on human NS have been conducted using recombinant protein purified from 
E. coli [8]. Curiously, in contrast to the studies conducted in vivo and in cell cultures models, purified 
NS efficiently polymerises in vitro even after short incubation times and at temperatures only slightly 
higher than the physiological 37 °C [24,25,32]. This suggests that, although technically convenient, 
bacterially expressed human NS does not reproduce the behaviour of this protein as observed in 
more physiologic contexts. These considerations highlighted the need to assess the role of the N-
glycosylation in the molecular properties of the human wild-type NS in vitro. Thus, in order to shed 
light on this conundrum, we report here for the first time the expression, purification and 
characterisation of recombinant N-glycosylated human NS (gNS) produced using LEXSY® 
(Leishmania tarentolae expression system), an eukaryotic expression system based on L. tarentolae cells 
[33]. N-glycosylation by Leishmania spp. is more equivalent to the mammalian counterpart compared 
to other model organisms, e.g., insect cells or fungi [33]. For this reason, the use of LEXSY is 
particularly suitable for the expression of human glycosylated protein.  
The presence of the correct glycosylation pattern and the conformational and biophysical 
properties of gNS were assessed in comparison with non-glycosylated bacterially purified NS, 
confirming the correct fold of the glycosylated variant (gNS). A marked reduction was observed in 
the heat-induced polymerisation propensity of gNS compared to NS. Finally, gNS displays a slightly 
increased efficiency in inhibiting tPA activity in vitro. Taken together, here, we produced a 
glycosylated version of NS that shares all molecular properties of native NS but, importantly, it better 
recapitulates NS polymerisation propensity, as observed in vivo and in cell models. Thus, gNS should 
be considered a valuable new in vitro tool to study NS polymerisation and its inhibition.  
2. Results and Discussion 
2.1. Expression and Purification of Glycosylated NS 
In order to successfully express human NS in the LEXSY system, a Leishmania-optimised 
sequence of the NS gene was cloned into pLEXSY-sat2, an integrative plasmid for constitutive 
expression. The NS gene was cloned in frame with a 6-His tag engineered at the N-terminus. To 
improve the amount of secreted protein, the commercial secretion signal peptide was substituted 
with the modified sequence of the SP5 signal peptide (Figure 1A) [34]. Once stable expressing clones 
were obtained, protein expression was carried out for 60 h at 26 °C. NS expressed in LEXSY (thereafter 
named gNS) was purified from the growth medium after removing intact cells and cellular debris. 
Two steps of chromatography were performed to isolate the gNS monomer: an initial Ni-NTA affinity 
chromatography (AC) was followed by a size exclusion chromatography step (SEC) (Figure S1A). 
About 7 mg of highly pure monomeric gNS was obtained per litre of LEXSY culture, but, undesirably, 
nearly 80% of the purified protein was in the cleaved form (Figure 1B). The addition of cocktails of 
protease inhibitors in the medium did not ameliorate the proteolytic pattern (data not shown).  
In vitro purified NS displayed a highly reproducible tendency to autoproteolysis over time, 
which is accelerated upon temperature increase (Figure S2). Thus, we hypothesise that the prolonged 
incubation of NS at 26 °C in LEXSY medium was responsible for this phenomenon. In order to 
minimize NS cleavage, the expression protocol was modified: after 60 h of culture, cells were 
collected, resuspended into fresh medium and incubated 16 h at 18 °C (Figure S1B). Next, purification 
steps were performed as reported above. The purification of gNS from such 16 h of growth resulted 
in a significantly increased amount of uncleaved native NS; however, the yield was reduced to 2 mg 
per litre of culture and a minor residual fraction of cleaved gNS was still present (Figure 1C).  
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Figure 1. Human glycosylated NS (gNS) expression and purification in LEXSY. (A) Primary sequence 
of the construct used for gNS expression in LEXSY (UniProtKB - Q99574). The signal peptide sequence 
is colored in blue, the HisTag is green and the spacer in grey. The neuroserpin (NS) sequence is black, 
the glycosylation sites are in red and the triangle highlights the protease cleavage site. (B) SDS-PAGE 
analysis of gNS purification after AC and SEC chromatographic steps according to the protocol shown 
in Figure S1A. (C) SDS-PAGE analysis of optimized gNS purification after the AC and SEC 
chromatographic steps (see also Figure S1B). Abbreviations: Nat: native; CL: cleaved; AC: affinity 
chromatography; SEC: size exclusion chromatography. 
2.2. gNS Is Properly Glycosylated  
The presence of appropriate glycosylation on LEXSY-expressed gNS was verified using several 
complementary techniques. First, the migration of gNS in denaturing polyacrylamide gel 
electrophoresis (SDS-PAGE) was delayed compared to NS (Figure 6D). The increment of molecular 
mass was in agreement with the presence of N-glycan chains.  
The presence of N-linked glycosylation was thereafter confirmed by enzymatic deglycosylation 
using peptide-N-glycosidase F (PNGaseF) and endoglycosidase H (EndoH). Both enzymes remove 
N-linked oligosaccharides, but with different specificities. The first enzyme is an amidase that 
removes all types of mammalian N-linked glycans, whereas EndoH removes only high-mannose and 
some hybrid types of N-linked glycans. As reported in Figure 2A, gNS was susceptible only to 
PNGaseF treatment, resulting in a faster migration in SDS-PAGE, whereas incubation with EndoH 
caused no reduction in molecular mass. Altogether, these results confirm the presence of N-
glycosylation along the secretory pathway and the delivery of gNS with mature glycans to the growth 
medium. In agreement, previously identified N-glycans from an L. tarentolae recombinant 
glycoprotein consisted mostly of the mammalian complex biantennary and the paucimannose 
Man3GlcNAc2 structures [33]; such glycans are known to be effectively cleaved by PNGase F but not 
by Endo H [35]. 
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Figure 2. Assessment of N-glycosylation. (A) SDS-PAGE analysis of the enzymatic deglycosylation of 
gNS using EndoH or PNGaseF deglycosylases. All samples are a mixture of native and cleaved forms. 
Black and white arrows refer to lane 1 (gNS) and lane 2 (PNGaseF), respectively. (B–C) Matrix-
assisted laser desorption ionisation-time of flight (MALDI-TOF) MS spectra of NS (B) and gNS. 
Abbreviations: Nat: native; Nat*: deglycosylated Nat; Cl: cleaved; Cl*: deglycosylated Cl. 
In order to determine the precise protein molecular mass, matrix-assisted laser desorption 
ionisation-time of flight (MALDI-TOF) MS analyses under native conditions were performed both on 
gNS and NS proteins. As shown in Figure 2C, the masses of native and cleaved NS, detected at 46,279 
and 40,624 Da, respectively, allow for clearly identifying the presence of the cleavage site at Arg362. 
Moreover, the masses of the gNS protein were detected at 48,033 Da and 41,615 Da for the native and 
cleaved protein forms, respectively (Figure 2B). The increment in the molecular mass of gNS 
compared to its theoretical mass unambiguously confirmed the presence of post-translational 
modifications in gNS.  
In order to map the glycosylation sites, the peptides obtained by the tryptic in-gel digestion of 
gNS were analysed by UHPLC-MS/MS. The identified gNS peptides, which provided a sequence 
coverage of 74%, are listed in Table S1 in the Supplementary Material. Two glycopeptides were 
detected (Table ST1 and Figure 3), corresponding to glycosylation sites at positions N157 and N321. 
These glycopeptides were not present in a similar analysis performed on gNS deglycosylated by 
PNGaseF (data not shown).  
Thus, the mass increment observed on gNS compared to NS was due to two occupied N-
glycosylation sites. Further experiments would be required to elucidate the corresponding glycan 
structures. 
Overall, these results confirmed that NS produced using the LEXSY expression system presents 
two N-glycosylations in the sites previously reported [30].  
Int. J. Mol. Sci. 2020, 21, 3235 6 of 16 
 
 
Figure 3. Identification of N-glycosylation sites. UHPLC-MS/MS analysis of glycopeptides 
WVENNTNNLVK (A,C) and DANLTGLSDNKEIFLSK (B,D). The peptides are detected in the MS 
spectrum as 2+ ion with m/z = 767.3906 (A) and 3+ ion with m/z = 757.7227 (B). These signals are 
selected and used as parent ions (PIs) for higher energy collision dissociation (HCD) fragmentation 
(C,D). Two glyco-diagnostic peaks are present in the fragmentation spectra (HexNAc, m/z 204.09; 
HexNAc fragment, m/z 126.05 Da), indicating that PIs are glycopeptides. Identified a-, b- and y-
fragment ions are labelled (*, loss of HexNAc during fragmentation; #, loss of HexNAc2 during 
fragmentation). 
2.3. Conformational Analysis of gNS 
The potential impact of N-glycosylation at residues N157 and N321 on protein structure was 
evaluated by assessing the secondary structures content of gNS and NS by circular dichroism (CD) 
analyses. Comparison of the far-UV spectra of gNS and NS is presented in Figure 4A. The two CD 
spectra perfectly superpose, suggesting that the heterologous expression in LEXSY produces 
properly folded gNS and that its secondary structure is virtually identical to those of previously 
characterised NS [6,7]. Even if bacterially expressed NS is not glycosylated, it represents a good 
reference for NS folding since it was reported that the glycan is not required for the acquirement and 
maintenance of the serpin fold [30]. Next, the stability and potential conformational changes of gNS 
were monitored by molar ellipticity at 216 nm, along a temperature ramp from 20 to 95 °C. While 
bacterial NS undergoes two irreversible transitions at 56.6 and 87.0 °C (Figure 4B in accordance with 
[24]), the gNS temperature ramp displays two very minor increases (more negative) in CD signal at 
about 60 and 93 °C (Figure 4C). The conformational changes underlying such signals are irreversible, 
as the CD signal becomes even more negative when the sample was cooled down (Figure 4C). This 
typically indicates a gain of secondary structure, connected with latentisation and/or polymerisation 
reminiscent of what was observed for bacterial NS [24]. The comparison of Far-UV CD spectra 
recorded before and after the temperature ramp indicate that the latter shows a stronger CD signal 
(Figure 4D). The more regular structure of the RCL in the latent and polymeric conformers likely 
accounts for the increased CD signal, as previously reported [24]. 
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It has been reported that intrinsic fluorescence can be informative of NS conformation [25]. For 
this reason, intrinsic tryptophan fluorescence was recorded to study gNS fold. The spectra of native 
or SEC-purified polymeric gNS are analysed and compared in Figure 4E. Native gNS presented a 
main peak at 330 nm, whereas, for the gNS polymers, a red shift and the quenching of the tryptophan 
signal were detected. These effects observed for polymeric gNS may be ascribed to an increased 
exposure of tryptophan residues in gNS polymers, similar to what has already been reported in the 
literature for bacterially expressed NS [7,25,36]. 
In conclusion, these data indicate that gNS is properly folded and that its overall structure 
closely resembles the one of bacterially expressed NS. 
 
Figure 4. Conformational characterisation of gNS. (A) Far-UV circular dichroism (CD) spectra of 
native gNS and NS recorded at 20 °C. (B,C) Temperature ramp of NS (B) analogously reported in [24] 
and gNS (C) performed recording ellipticity at 216 nm during heating from 20 to 95 °C (black) and 
cooling down (grey). The first derivative is reported in the bottom (blue) and the two transitions T1 
and T2 are highlighted by the red arrows. (D) Far-UV CD spectra of gNS recorded at 20 °C before 
(black) or after (green) heating the sample to 95 °C. (E) Intrinsic tryptophan fluorescence of native 
(solid line) and polymeric (dashed line) gNS recorded at 20 °C. The buffer 20 mM Tris-HCl pH 8, 50 
mM KCl was used in all the measurements. 
2.4. gNS Inhibits tPA In Vitro 
Then the ability of gNS to inhibit tPA in vitro was assessed. The activity of tPA on its 
chromogenic substrate IPR-pNA was measured in the presence or absence of gNS or NS, monitoring 
absorbance at 405 nm. While in the absence of NS or gNS the absorbance due to IPR-pNA hydrolysis 
rapidly reached a plateau, in the presence of gNS and NS, the absorbance at 405 nm increased more 
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slowly and remained almost constant, indicating that both NS and gNS displayed similar inhibitory 
activity against tPA (Figure 5A). The inhibition of tPA by a sample of gNS incubated for 24 h at 45 °C 
was also tested and tPA was completely active when compared to the control reaction (Figure 5A), 
indicating that, during incubation, gNS has lost its inhibitory activity. This is likely due to the 
formation of the inactive polymer and latent forms and the concomitant disappearance of native gNS. 
 
Figure 5. Comparison of tissue plasminogen activator (tPA) inhibition by NS and gNS. (A) tPA 
activity tests in the absence (red) and presence of 60 nM of NS (blue), native (green) or incubated for 
24 h at 45 °C (grey) gNS. (B) The ability of gNS and NS to inhibit tPA at two different concentrations 
(75 and 150 nM) was compared. (C) The inhibitory efficiency of gNS or NS is reported in comparison 
to the control reaction. The activity of tPA in the positive control after 56 h is set to 100% and all other 
values have been normalised accordingly. In the control reaction, no gNS or NS was added. 
The inhibition of tPA by gNS and NS was tested for longer times and at different concentrations 
(Figure 5B,C). It is apparent that gNS is a marginally more efficient inhibitor of tPA proteolytic 
activity since the substrate was hydrolysed more slowly in the presence of gNS than in the presence 
of NS (Figure 5B). Figure 5C shows more quantitively than panel 5B the different tPA inhibitions by 
NS and gNS. The percentage of active tPA at different times of incubation is reported in comparison 
with the control reaction without inhibitors. During the first 24 h of incubation time, the comparison 
of tPA activity in the presence of gNS or NS shows marked differences at both concentrations tested. 
In particular, curves in Figure 5B show that, after about 15 h, substrate hydrolysis by tPA is markedly 
increasing in the presence of NS, while, in the presence of gNS, tPA activity grows more slowly, 
displaying lower rate of hydrolysis for the first 50 h. At the end of the experiment (56 h), the difference 
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in inhibitory efficiency tends to level up even though gNS was still a marginally better inhibitor than 
NS (Figure 5B,C). These observations strongly suggest a higher stability—i.e., slower rate of 
hydrolysis—of the gNS-tPA covalent complex compared to the one formed by NS-tPA. Although the 
gNS-tPA complex remains transient, the presence of the two N-glycans seem to stabilise the tPA-gNS 
complex with a consequent slower deacylation rate [14]. The full description of this observation and 
the molecular bases of this stabilisation by the presence of the glyco-antennas will require further 
characterisation in a future work. 
2.5. Glycosylation Reduces Heat-Induced Polymerisation of gNS 
The role of glycosylation during the heat-induced polymerization process was next evaluated. 
Solutions of gNS and NS at a concentration of 63.8 μM were incubated at 45 °C and the presence of 
polymeric species was assessed at different time points using SEC and both non-denaturing and 
denaturing PAGE (Figure 6). Most of the bacterially purified NS was already assembled into large 
polymeric species after 3 h of incubation and only a minor peak corresponding to monomeric NS was 
visible (Figure 6A). Non-denaturing PAGE confirmed the presence of very large polymers, as they 
were barely entering in the non-denaturating PAGE (Figure 6C). The denaturing PAGE analysis of 
aliquots of the same samples assessed the SDS-solubility of these species (Figure 6D). Thus, as 
previously shown [24], at 45 °C, NS undergoes rapid conformational changes, leading to the 
formation of a great excess of polymers over the latent conformer.  
In contrast, gNS displayed a remarkably different behaviour. First, even after 24 h of incubation, 
only a minor amount of polymeric form was detected by SEC (Figure 4B) and non-denaturing PAGE 
(Figure 4C). Moreover, polymers formed by gNS were eluted at 10–12 mL in SEC, in contrast to the 
large polymers formed by bacterially purified NS that were eluted into the dead volume of the 
column (Figure 6B). Analogously, in non-denaturating PAGE, gNS polymers displayed an apparent 
lower mass range (Figure 6C) compared to polymers formed by bacterially expressed NS. When 
analysed by denaturing PAGE, the gNS polymers dissolved and migrated as monomeric gNS, as 
observed for the bacterially purified counterpart (Figure 6D). It should be noted that, even though a 
small amount of polymers was observed upon incubation at 45 °C, most of the gNS remained 
monomeric, as shown in SEC and non-denaturating gel (Figure 6B,C). The different migration of gNS 
in the non-denaturating gel suggests that the native conformer disappears over time (Figure 6C). 
Overall, these data indicate that, in the presence of glycosylation, polymer formation is greatly 
reduced. Importantly, gNS polymerisation propensity is in line with previous observations in vivo 
and in cell models of FENIB where wild-type NS does not accumulate in polymeric deposits [26,37]. 
These results reinforce the hypothesis that the presence of glycan is crucial in preventing aberrant 
interaction between NS monomers [30]. 
The lack of inhibitory activity observed in vitro by incubated gNS (Figure 5A) suggests that the 
native gNS undergoes a conformational change resulting in the formation of the inactive latent 
conformation, as also suggested by Figure 6C.  
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Figure 6. Heat-induced polymerisation of gNS. A solution of gNS or NS was incubated at 45 °C and 
analysed at different time points. SEC analysis of NS (A) or gNS (B) using an Increase Superdex 200 
column. Aliquots of NS or gNS were analysed by non-denaturing (C) and denaturing (D) PAGE. 
Abbreviations: Nat: native; Cl: cleaved; Lat: latent; Pol: polymers. 
3. Materials and Methods 
3.1. LEXSY Plasmid and Strain 
The cassette containing the sequence of the human NS gene optimized for Leishmainia tarentolae 
codon bias, in fusion at the N-terminus with the sequence for the secretion signal peptide (5′-
ATGGCTAGCCGTCTCGTCCGGGTGCTCGCAGCGGCAATGCTGGTGGCAGCCGCTGTCTCCGT
CGCAATGGCC-3′) and the 6-His tag, was sub-cloned into the pLEXSY-sat2 plasmid (Jena Bioscience, 
Jena, Germany) using NcoI and Kdel restriction enzymes (New England Lab, NEB, Ipswich, MA, 
USA). pCloneGZ/NS and pLEXSY-sat2 were digested with NcoI and Kdel. The digestion products 
were gel-purified and ligated using the Quik Ligation kit (NEB). The resulting pLEXSY-sat2/NS 
plasmid was linearized with SwaI restriction enzyme (Thermo Fisher Scientific, Waltham, MA, USA). 
All the amplification steps were performed in E. coli XL1 cells (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA) at 30 °C for plasmid stability reasons. LEXSY host P-10 cells (Jena Biosciences) 
were transfected with linearized pLEXSY-sat2/NS plasmid and plated on freshly prepared agar plates 
(40 mM Hepes pH 7.4, 26 g/L brain heart infusion, 10% inactivated fetal calf serum, 1% bactoagar, 50 
μg/mL hemin, 1 unit/mL penicillin and 0.1 mg/mL streptomycin, 100 μg/mL nourseothricin, NTC). 
After 2 weeks at 26 °C, colonies were inoculated into Brain Heart Infusion (BHI) medium 
supplemented with 50 μg/mL hemin, 1 unit/mL penicillin, 100 μg/mL streptomycin (BHI-complete 
medium) and 100 μg/mL NTC.  
Protein expression was evaluated by dot-blot using monoclonal anti-NS(m19) primary antibody 
and HRP-coupled anti-rabbit IgG. Membranes were developed using Pierce ECL Western Blotting 
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substrate (Thermo Fisher Scientific, Waltham, MA, USA). All chemicals were purchased from Sigma 
Aldrich (St. Louise, MO, USA), and NTC was bought from Jena Bioscience.   
3.2. gNS Expression and Purification 
Transformed LEXSY cells were cultured at 26 °C in BHI complete medium, always added with 
NTC, in a ventilated tissue flask in static suspension in the dark. Cultures were split two times a week 
with a 1:20 dilution into fresh medium. For large-scale protein expression, cells were cultured 50 h 
under 220 rpm shaking at 26 °C in the dark and then collected by centrifugation during 15 min at 
4500 g. The cell pellet was resuspended in the same volume of fresh BHI-complete medium and 
incubated for 16 h at 18 °C. Finally, cells were collected 15 min at 10,500 g and the supernatant was 
concentrated using an Amicon Millipore ultrafiltration system. Concentrated culture medium was 
dialyzed against buffer A (20 mM Tris-HCl pH 8.0, 10 mM imidazole, 300 mM NaCl) to remove hemin 
and loaded onto a 5-mL HiTrap Chelating HP Amersham column (GE Healthcare, Chicago, IL, USA) 
previously equilibrated with the same buffer. Proteins were eluted in buffer B (20 mM Tris-HCl pH 
8.0, 250 mM imidazole, 300 mM NaCl) after a washing step at 10% of buffer B. Monomers were further 
isolated by gel filtration using an Hi Load 16/60 Superdex200 column (GE Healthcare) equilibrated 
in 10 mM Tris-HCl, 50 mM KCl, pH 8.0. All purifications steps were performed at 4 °C. All chemicals 
were purchased from Sigma-Aldrich, unless differently specified. NS concentration was measured 
by optical absorption using an extinction coefficient at 280 nm of 37,360 M−1 cm−1. Due to the 
impossibility to obtain a completely native sample of gNS, all experiments comparing gNS and 
bacterially expressed NS were performed using a mix of native and cleaved NS in a ratio similar to 
gNS samples allowing reliable comparisons. 
3.3. NS Expression and Purification 
E. coli BL21 Rosetta (DE3) pLysS Competent Cells Novagen (Merck KGaA) transformed with 
pQE81L plasmid carrying the human NS gene with a N-terminus 6-His tag were used to express and 
purify NS as reported in [6]. Briefly, bacterial cells were grown in Superior Broth (Molecular 
Dimension) containing 100 μg/mL ampicillin, and protein expression was induced with 0.2 mM 
isopropyl-β-D-thiogalactopyranoside at 17 °C for 16 h. NS was purified from the soluble fraction. 
Buffer A supplemented with cOmplete protease inhibitor cocktail (Hoffmann-La Roche, Basel, 
Switzerland) was added, and the cell pellets were immediately sonicated. Crude extract was clarified 
by centrifugation and filtered before being loaded onto a 1-mL HiTrap Chelating HP column (GE 
Healthcare) previously equilibrated with buffer A. Protein was eluted in 100% buffer B. Monomers 
were further isolated by gel filtration using an Hi Load 16/60 Superdex200 column (GE Healthcare) 
equilibrated in 10 mM Tris-HCl, 50 mM KCl, pH 8.0. All purification steps were performed at 4 °C 
and all chemicals were purchased from Sigma-Aldrich, unless differently specified. NS concentration 
was measured by optical absorption using an extinction coefficient at 280 nm of 37,360 cm−1 M−1.  
3.4. NS Autoproteolysis Assay 
A solution of 63.8 μM of NS in 10 mM Tris-HCl, 50 mM KCl, pH 8 or 7.6 was incubated at 26 °C 
or 37 °C. At different time of incubation, an aliquot was subjected to denaturing-PAGE. Gels were 
stained with Coomassie Brilliant Blue R-250. The experiment was repeated at least three times, and 
representative gel is reported. 
3.5. Deglycosylation Assay 
Deglycosylation was performed using a peptide-N Glycosydase F (PNGase) deglycosylation kit 
(NEB) in non-denaturing conditions or an endoglycosydase H (EndoH) deglycosylation kit (NEB). 
According to the manufacturer’s instruction, 10 μg of gNS was diluted in GlycoBuffer and 2 μl of 
PNGaseF was added. Protein mix was incubated at 37 °C for 16 h before SDS-PAGE analysis. For 
EndoH digestion, 10 μg of gNS were diluted in Glycoprotein denaturing buffer and incubated 10 min 
at 80 °C prior to the addition of 2 μL of the enzyme. The mixture was incubated 5 h at 37 °C and 
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analysed by SDS-PAGE. In both assays, a solution of 10 μg gNS were prepared in the same 
experimental conditions but with no enzyme as a negative control. The experiment was repeated at 
least three times and representative gels are reported. 
3.6. MALDI-TOF MS Analysis 
Matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass analysis was 
carried out on concentrated NS or gNS solutions. NS and gNS constructs have slightly different 
Histag constructs: the theoretical mass is 46,271 and 45,810 Da, respectively. Purified protein samples 
were diluted with 0.1% trifluoroacetic acid in water (TFA) to a final concentration of 10 pmol/μL, 
prior protein precipitation with 50% trichloroacetic acid (TCA). Each sample was loaded onto a 
MALDI target plate using the dry droplet technique and sinapinic acid (SA) in 0.1% TCA:acetonitrile 
(2:1) as matrix. Mass spectrometry analysis was carried out by a Bruker Daltonics Reflex III 
instrument (Bruker Daltonics, Billerica, MA, USA) equipped with a nitrogen laser (337 nm), operating 
in linear positive mode. Each spectrum was accumulated for at least 200 laser shots and protein 
calibration standards II (Bruker Daltonics) were used for calibration [38]. The PeptideMass tool 
(http://www.expasy.org/tools/peptide-mass.html) was used to calculate the theoretical masses of 
native and cleaved NS and gNS proteins and for identifying NS cleavage site.   
3.7. UHPLC-MS/MS Analysis  
Ultra performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) 
analysis were performed on gNS and deglycosylated tryptic peptides obtained by a standard in-gel 
digestion protocol [39] applied on gel bands of gNS and gNS deglycosylated with PNGaseF. After 
digestion, the peptides were desalted by C18 Ziptips (Millipore, Burlington, MA, USA) and injected 
on an Orbitrap Fusion mass spectrometer equipped with a nano-UHPLC system EASY 1000 
(Thermofisher). Peptides were separated by a 1-h gradient (aqueous phase: milliQ water, 0.1% formic 
acid; organic phase: 80% acetonitrile, 20% milliQ water, 0.1% formic acid), detected by the orbitrap 
analyzer, and subjected to a first fragmentation step by Higher energy Collision Dissociation (HCD). 
The corresponding HCD fragmentation spectra allowed the for identification of unmodified peptides 
by the software Proteome Discoverer (Thermo Fisher). In the case of glycopeptides, instead, HCD 
fragmentation mainly generates intense reporter ions of the glyco-antenna, e.g., HexNAc, 204.09 Da. 
This feature was exploited to selectively trigger a second fragmentation step by EThcD, a combination 
of HCD and Electron Transfer Dissociation (ETD), in order to better identify the peptide sequence 
and map the modification site [40]. 
3.8. Circular Dichroism Analysis 
CD measurements were carried out on 4.5 μM NS or gNS in 10 mM Tris-HCl, 50 mM KCl, pH 
8.0, by a J-810 spectropolarimeter (Jasco, Mary's Court Easton, MD, USA) equipped with a PFD-425S 
temperature controller module (Jasco), in a 0.1 cm path-length cuvette. Temperature ramps ware 
performed recording ellipticity at 216 nm during sample heating from 20 to 95 °C and following 
cooling from 95 to 20°C (temperature slope 1.0 °C/min). First, the derivative of the data has been 
calculated and plotted to determine the temperature of transitions.  
3.9. Intrinsic Protein Fluorescence Assay 
The intrinsic tryptophan fluorescence of 11 μM monomeric or polymeric gNS was measured in 
a FP-8200 spectro-fluorimeter (Jasco) at 20 °C. Emission spectra from 310 to 410 nm were recorded 
and 295 nm was used as an excitation wavelength. Each trace is the average of the accumulation of 
three spectra. 
3.10. Polymerisation Assay  
Solution of 63.8 μM NS or gNS in 10 mM Tris-HCl pH 8.0 and 50 mM KCl were incubated at 45 
°C. Aliquots at different incubation time were collected and analysed by size exclusion 
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chromatography (SEC) using a Superdex 200 Increase 10/300 GL column (GE Healthcare Europe 
GmbH). An aliquot of each sample was subsequently subjected to non-denaturating polyacrylamide 
gel electrophoresis. The experiment was repeated at least three times and representative gels are 
reported. 
3.11. Non-denaturating Polyacrylamide Gel Electrophoresis (PAGE) 
Samples were prepared as previously reported [41]. Briefly, aliquots of gNS or NS at different 
times of incubation at 45 °C were collected and mixed at a 1:1 volume ratio with a non-denaturing 
loading buffer (250mM Tris-HCl, 50% glycerol, 0.5% bromophenol blue, pH 6.8). Samples were 
separated into 7.5 % non-denaturating polyacrylamide gels run at 90 V for 2 h at 4 °C to prevent 
sample denaturation and/or polymer dissociation. Gels were stained with Coomassie Brilliant Blue 
R-250. The experiment was repeated at least three times and representative gels are reported. 
3.12. Inhibitory Activity Test 
The inhibition of two-chain tissue plasminogen activator (2ctPA, American Diagnostica, 
Pfungstadt, Germany) by NS or gNS was determined in the presence of the chromogenic substrate 
H-D-Ile-Pro-Arg-p-nitroanilide (IPR-pNA; Chromogenix, Werfer,  L'Hospitalet de Llobregat, Spain) 
by recording the pNA accumulation upon substrate cleavage. The reaction was prepared mixing 60, 
75 or 150 nM NS, 250 μM IPR-pNA, 1 nM 2ctPA in 50 mM Tris-HCl pH 7.4, 10 mM Na2HPO4, 150 
mM NaCl, and 0.1% Tween and incubated at 25 °C [42]. The reaction was monitored at 405 nm in an 
Ultraspec 2100 Pro spectrophotometer (Amersham Bio, Little Chalftont, UK). The curves shown are 
representative of all the performed experiments.  
4. Conclusions 
In summary, we report here the expression, purification and characterisation of human N-
glycosylated NS. Recombinant gNS is properly glycosylated in the physiologic positions N154 and 
N321, which were previously identified [30]. Moreover, gNS is properly folded and it is a marginally 
better in vitro inhibitor of tPA activity than non-glycosylated NS. Crucially, the presence of the two 
N-glycosylation chains impacts gNS propensity to pathologic polymerisation. More specifically, 
while non-glycosylated NS efficiently forms polymers in vitro, the formation of gNS polymers is slow 
and marginal. Although the present data do not provide a detailed explanation for this observation, 
gNS low polymerisation propensity may be due to the steric hindrance of the two glycan chains and 
to the slight increase in gNS fold stability, as seen in Figure 4B,C. Here, we show that the artifactual 
polymerisation propensity observed for wild-type NS expressed in bacteria is due to the absence of 
a proper glycosylation, while gNS displays a behaviour closely resembling what has been observed 
in vivo and in cell systems. Thus, gNS may be seen as a valuable tool to properly characterise the 
polymerisation propensity of the FENIB mutants in vitro. 
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Abbreviations 
AC Affinity chromatography 
CD Circular dichroism 
Cl Cleaved neuroserpin 
EndoH Endoglycosidase H 
FENIB Familial encephalopathy with neuroserpin inclusion bodies 
Frag Proteolytic neuroserpin fragment 
gNS Glycosylated NS 
Lat Latent neuroserpin 
LEXSY Leishmania expression system 
MALDI-TOF 
MS 
Matrix Assisted Laser Desorption/Ionization - Time of Flight Mass 
Spectrometry 
Nat Native neuroserpin 
NS Neuroserpin  
PNGaseF Peptide -N-Glycosidase F 
Pol Polymeric neuroserpin 
RCL Reactive centre loop 
SDS-PAGE Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
SEC Size exclusion chromatography 
SERPIN Serine Protease Inhibitor 
tPA Tissue Plasminogen Activator 
UHPLC MS/MS Ultra high performance liquid chromatography - tandem mass spectrometer 
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